Julius Popp

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


158 publications

In press | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2004 | 1998 |
In press
 
X-chromosome-wide association study for Alzheimer's disease.
Le Borgne J., Gomez L., Heikkinen S., Amin N., Ahmad S., Choi S.H., Bis J., Grenier-Boley B., Rodriguez O.G., Kleineidam L. et al. Molecular psychiatry. Peer-reviewed.
[DOI][Pmid][serval:BIB_95DD4D5D9C2A]
 
Neuropsychiatric symptoms in cognitive decline and Alzheimer's disease: biomarker discovery using plasma proteomics.
Rabl M., Clark C., Dayon L., Popp J., Alzheimer's Disease Neuroimaging Initiative Journal of neurology, neurosurgery, and psychiatry. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D8FFCBBF9B53]
2024
 
Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study.
Smith R.G., Pishva E., Kouhsar M., Imm J., Dobricic V., Johannsen P., Wittig M., Franke A., Vandenberghe R., Schaeverbeke J. et al., 2024/10. Alzheimer's & dementia, 20 (10) pp. 6722-6739. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8DB8DBD5DA45]
Blood-based multivariate methylation risk score for cognitive impairment and dementia.
Koetsier J., Cavill R., Reijnders R., Harvey J., Homann J., Kouhsar M., Deckers K., Köhler S., Eijssen LMT, van den Hove DLA et al., 2024/10. Alzheimer's & dementia, 20 (10) pp. 6682-6698. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A14021C3A90F]
 
CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease.
Delvenne A., Gobom J., Schindler S.E., Kate M.T., Reus L.M., Dobricic V., Tijms B.M., Benzinger TLS, Cruchaga C., Teunissen C.E. et al., 2024/09. Alzheimer's & dementia, 20 (9) pp. 6205-6220. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B6F71BC8718A]
 
Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
Rabl M., Zullo L., Lewczuk P., Kornhuber J., Karikari T.K., Blennow K., Zetterberg H., Bavato F., Quednow B.B., Seifritz E. et al., 2024/07/25. Alzheimer's research & therapy, 16 (1) p. 165. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5F9B8537E029]
 
Involvement of the choroid plexus in Alzheimer's disease pathophysiology: findings from mouse and human proteomic studies.
Delvenne A., Vandendriessche C., Gobom J., Burgelman M., Dujardin P., De Nolf C., Tijms B.M., Teunissen C.E., Schindler S.E., Verhey F. et al., 2024/07/18. Fluids and barriers of the CNS, 21 (1) p. 58. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AA3F1D78EAA6]
Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease.
Gómez-Pascual A., Naccache T., Xu J., Hooshmand K., Wretlind A., Gabrielli M., Lombardo M.T., Shi L., Buckley N.J., Tijms B.M. et al., 2024/06. Computers in biology and medicine, 176 p. 108588. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_077225355F97]
Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
Rabl M., Zullo L., Lewczuk P., Kornhuber J., Karikari T.K., Blennow K., Zetterberg H., Bavato F., Quednow B.B., Seifritz E. et al., 2024/03/22..
[URN][DOI][Pmid][serval:BIB_7DED5DF24896]
Cholesterol-metabolism, plant sterols, and long-term cognitive decline in older people - Effects of sex and APOEe4.
Spinedi M., Clark C., Zullo L., Kerksiek A., Pistis G., Castelao E., von Gunten A., Preisig M., Lütjohann D., Popp J., 2024/02/16. iScience, 27 (2) p. 109013. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_16C028B993EA]
2023
Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning.
Neumann A., Ohlei O., Küçükali F., Bos I.J., Timsina J., Vos S., Prokopenko D., Tijms B.M., Andreasson U., Blennow K. et al., 2023/10/04. Genome medicine, 15 (1) p. 79. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4266F7D342DB]
Multiancestry analysis of the HLA locus in Alzheimer's and Parkinson's diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes.
Le Guen Y., Luo G., Ambati A., Damotte V., Jansen I., Yu E., Nicolas A., de Rojas I., Peixoto Leal T., Miyashita A. et al., 2023/09/05. Proceedings of the National Academy of Sciences of the United States of America, 120 (36) pp. e2302720120. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_017FA8B8CC9B]
Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease.
Shi L., Xu J., Green R., Wretlind A., Homann J., Buckley N.J., Tijms B.M., Vos SJB, Lill C.M., Kate M.T. et al., 2023/08. Alzheimer's & dementia, 19 (8) pp. 3350-3364. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C8A230E9823A]
Plant sterols and cholesterol metabolism are associated with five-year cognitive decline in the elderly population.
Clark C., Gholam M., Zullo L., Kerksiek A., Castelao E., von Gunten A., Preisig M., Lütjohann D., Popp J., 2023/06/16. iScience, 26 (6) p. 106740. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D67A741E91C1]
Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits.
Küçükali F., Neumann A., Van Dongen J., De Pooter T., Joris G., De Rijk P., Ohlei O., Dobricic V., Bos I., Vos SJB et al., 2023/06. Alzheimer's & dementia, 19 (6) pp. 2317-2331. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_763183AEC0D7]
Genetic Associations Between Modifiable Risk Factors and Alzheimer Disease.
European Alzheimer's & Dementia Biobank Mendelian Randomization (EADB-MR) Collaboration, Luo J., Thomassen J.Q., Bellenguez C., Grenier-Boley B., de Rojas I., Castillo A., Parveen K., Küçükali F., Nicolas A. et al., 2023/05/01. JAMA network open, 6 (5) pp. e2313734. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BC107414CB46]
Obstructive sleep apnoea and 5-year cognitive decline in the elderly.
Marchi N.A., Solelhac G., Berger M., Haba-Rubio J., Gosselin N., Vollenweider P., Marques-Vidal P., Popp J., von Gunten A., Preisig M. et al., 2023/04. The European respiratory journal, 61 (4) p. 2201621. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1104ABE24D6A]
Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.
de Rojas I., Moreno-Grau S., Tesi N., Grenier-Boley B., Andrade V., Jansen I.E., Pedersen N.L., Stringa N., Zettergren A., Hernández I. et al., 2023/02/09. Nature communications, 14 (1) p. 716. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_290CBDCBBC55]
 
Blood plasma protein profiles of neuropsychiatric symptoms and related cognitive decline in older people.
Rabl M., Clark C., Dayon L., Bowman G.L., Popp J., 2023/01. Journal of neurochemistry, 164 (2) pp. 242-254. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_46C4F1E79669]
2022
Persisting neuropsychiatric symptoms, Alzheimer's disease, and cerebrospinal fluid cortisol and dehydroepiandrosterone sulfate.
Ouanes S., Rabl M., Clark C., Kirschbaum C., Popp J., 2022/12/19. Alzheimer's research & therapy, 14 (1) p. 190. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7F388AFE5B07]
Biomarqueurs des pathologies neurodégénératives dans le diagnostic des troubles cognitifs - Revue et recommandations de Swiss Memory Clinics [Biomarkers for the diagnosis of cognitive impairment - Recommendations from the Swiss Memory Clinics]
Popp J., Georgescu D., Bürge M., Mundwiler-Pachlatko E., Bernasconi L., Felbecker A., 2022/12/14. Revue medicale suisse, 18 (808) pp. 2400-2405. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_13B0A1F498AD]
Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers.
Jansen I.E., van der Lee S.J., Gomez-Fonseca D., de Rojas I., Dalmasso M.C., Grenier-Boley B., Zettergren A., Mishra A., Ali M., Andrade V. et al., 2022/11. Acta neuropathologica, 144 (5) pp. 821-842. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2F3F6E6D5A81]
Characteristics of subjective cognitive decline associated with amyloid positivity.
Janssen O., Jansen W.J., Vos SJB, Boada M., Parnetti L., Gabryelewicz T., Fladby T., Molinuevo J.L., Villeneuve S., Hort J. et al., 2022/10. Alzheimer's & dementia, 18 (10) pp. 1832-1845. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D70F024AB648]
Recommandations pour la prévention, le diagnostic et la thérapie des addictions à l’âge avancé [Recommendations for the prevention, diagnosis, and therapy of addiction in the elderly]
Popp J., Fuchs A., Hemmeter U., Ibach P.B., Indermaur E., Klöppel S., Laimbacher S., Latanioti M., Leyhe T., Lötscher C. et al., 2022/09/28. Revue medicale suisse, 18 (797) pp. 1817-1824. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_76887AD35A72]
 
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease.
Le Guen Y., Belloy M.E., Grenier-Boley B., de Rojas I., Castillo-Morales A., Jansen I., Nicolas A., Bellenguez C., Dalmasso C., Küçükali F. et al., 2022/07/01. JAMA neurology, 79 (7) pp. 652-663. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0C058ADEF04A]
Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology.
Delvenne A., Gobom J., Tijms B., Bos I., Reus L.M., Dobricic V., Kate M.T., Verhey F., Ramakers I., Scheltens P. et al., 2022/06/14. Alzheimer's & dementia, 19 (3) pp. 807-820. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6984A7C83F93]
Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people.
Clark C., Richiardi J., Maréchal B., Bowman G.L., Dayon L., Popp J., 2022/05/28. Journal of neuroinflammation, 19 (1) p. 127. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8E3700B6EFDF]
Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.
Visser P.J., Reus L.M., Gobom J., Jansen I., Dicks E., van der Lee S.J., Tsolaki M., Verhey FRJ, Popp J., Martinez-Lage P. et al., 2022/05/13. Molecular neurodegeneration, 17 (1) p. 37. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_86C858061844]
 
Long-term stability and age-dependence of six regulatory serum proteins.
Menne F., Schipke C.G., Clark C., Popp J., 2022/05. Biomarkers in medicine, 16 (7) pp. 511-521. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_33DF2397AA31]
New insights into the genetic etiology of Alzheimer's disease and related dementias.
Bellenguez C., Küçükali F., Jansen I.E., Kleineidam L., Moreno-Grau S., Amin N., Naj A.C., Campos-Martin R., Grenier-Boley B., Andrade V. et al., 2022/04. Nature genetics, 54 (4) pp. 412-436. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_61669EC14E3F]
Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation.
Neumann A., Küçükali F., Bos I., Vos SJB, Engelborghs S., De Pooter T., Joris G., De Rijk P., De Roeck E., Tsolaki M. et al., 2022/04. Molecular psychiatry, 27 (4) pp. 1990-1999. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0975E24A344E]
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.
Visser P.J., Reus L.M., Gobom J., Jansen I., Dicks E., van der Lee S.J., Tsolaki M., Verhey FRJ, Popp J., Martinez-Lage P. et al., 2022/03/28. Molecular neurodegeneration, 17 (1) p. 27. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D9B62E11A8A5]
Cerebrospinal Fluid Proteome Alterations Associated with Neuropsychiatric Symptoms in Cognitive Decline and Alzheimer's Disease.
Mroczek M., Clark C., Dayon L., Bowman G.L., Popp J., 2022/03/18. Cells, 11 (6) p. 1030. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_90C5BE4B5973]
 
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
Jansen W.J., Janssen O., Tijms B.M., Vos SJB, Ossenkoppele R., Visser P.J., Amyloid Biomarker Study Group, Aarsland D., Alcolea D., Altomare D. et al., 2022/03/01. JAMA neurology, 79 (3) pp. 228-243. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_03FD3577DA18]
 
Biomarker in der Diagnostik kognitiver Störungen – Empfehlungen der Swiss Memory Clinics [Biomarkers for the diagnosis of cognitive impairment - Recommendations from the Swiss Memory Clinics]
Popp J., Georgescu D., Bürge M., Mundwiler-Pachlatko E., Bernasconi L., Felbecker A., 2022. Praxis, 111 (13) pp. 738-744. Peer-reviewed.
[DOI][Pmid][serval:BIB_76177F13F99E]
Cerebrospinal Fluid Cortisol and Dehydroepiandrosterone Sulfate, Alzheimer's Disease Pathology, and Cognitive Decline.
Ouanes S., Clark C., Richiardi J., Maréchal B., Lewczuk P., Kornhuber J., Kirschbaum C., Popp J., 2022. Frontiers in aging neuroscience, 14 p. 892754. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4BE70E51524E]
Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition.
Wesenhagen KEJ, Gobom J., Bos I., Vos SJB, Martinez-Lage P., Popp J., Tsolaki M., Vandenberghe R., Freund-Levi Y., Verhey F. et al., 2022. Alzheimer's & dementia, 14 (1) pp. e12286. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_79838A598CFA]
Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.
Homann J., Osburg T., Ohlei O., Dobricic V., Deecke L., Bos I., Vandenberghe R., Gabel S., Scheltens P., Teunissen C.E. et al., 2022. Frontiers in aging neuroscience, 14 p. 840651. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BEB9260E3023]
Predicting AT(N) pathologies in Alzheimer's disease from blood-based proteomic data using neural networks.
Zhang Y., Ghose U., Buckley N.J., Engelborghs S., Sleegers K., Frisoni G.B., Wallin A., Lleó A., Popp J., Martinez-Lage P. et al., 2022. Frontiers in aging neuroscience, 14 p. 1040001. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B26F1606764D]
The promise of multi-omics approaches to discover biological alterations with clinical relevance in Alzheimer's disease.
Clark C., Rabl M., Dayon L., Popp J., 2022. Frontiers in aging neuroscience, 14 p. 1065904. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_119CE5A59551]
2021
Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort.
Xu J., Green R., Kim M., Lord J., Ebshiana A., Westwood S., Baird A.L., Nevado-Holgado A.J., Shi L., Hye A. et al., 2021/11/03. Biomedicines, 9 (11) p. 1610. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2E8956BABE3D]
 
TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels.
Hong S., Dobricic V., Ohlei O., Bos I., Vos SJB, Prokopenko D., Tijms B.M., Andreasson U., Blennow K., Vandenberghe R. et al., 2021/10. Alzheimer's & dementia, 17 (10) pp. 1628-1640. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CA4AD3F89C29]
 
Replication study of plasma proteins relating to Alzheimer's pathology.
Shi L., Winchester L.M., Westwood S., Baird A.L., Anand S.N., Buckley N.J., Hye A., Ashton N.J., Bos I., Vos SJB et al., 2021/09. Alzheimer's & dementia, 17 (9) pp. 1452-1464. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B5EE9E09DA36]
CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals.
Tijms B.M., Gobom J., Teunissen C., Dobricic V., Tsolaki M., Verhey F., Popp J., Martinez-Lage P., Vandenberghe R., Lleó A. et al., 2021/08/02. Proteomes, 9 (3) p. 36. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_493D4EF14A21]
 
Factors associated with subjective cognitive decline in dementia-free older adults-A population-based study.
Zullo L., Clark C., Gholam M., Castelao E., von Gunten A., Preisig M., Popp J., 2021/08. International journal of geriatric psychiatry, 36 (8) pp. 1188-1196. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5D04808FC0B4]
Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.
de Rojas I., Moreno-Grau S., Tesi N., Grenier-Boley B., Andrade V., Jansen I.E., Pedersen N.L., Stringa N., Zettergren A., Hernández I. et al., 2021/06/07. Nature communications, 12 (1) p. 3417. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AEF4F55D3F31]
 
The power of personality in successful ageing: a comprehensive review of larger quantitative studies.
Pocnet C., Popp J., Jopp D., 2021/06. European Journal of Ageing, 18 (2) pp. 269-285. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B0E8BE3AF0C6]
An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer's disease.
Clark C., Dayon L., Masoodi M., Bowman G.L., Popp J., 2021/04/01. Alzheimer's research & therapy, 13 (1) p. 71. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5982CEEBF53C]
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C., Lewczuk P., Kornhuber J., Richiardi J., Maréchal B., Karikari T.K., Blennow K., Zetterberg H., Popp J., 2021/03/25. Alzheimer's research & therapy, 13 (1) p. 65. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0A145DCFFCB1]
 
Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression.
Jahn T., Clark C., Kerksiek A., Lewczuk P., Lütjohann D., Popp J., 2021/01. The Journal of steroid biochemistry and molecular biology, 205 p. 105785. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7CB2F980F7D1]
Empfehlungen für die Diagnostik und Therapie psychotischer Erkrankungen im Alter [Recommendations for the Diagnosis and Therapy of Psychotic Disorders in the Elderly]
Klöppel S., Savaskan E., Annoni J.M., Berruex J.L., Bohli L., Eder M., Hemmeter U., Hirsbrunner T., Leyhe T., Neyenhuys A. et al., 2021. Praxis, 110 (14) pp. 816-825. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_94FF00ECECAC]
Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies.
Shi L., Buckley N.J., Bos I., Engelborghs S., Sleegers K., Frisoni G.B., Wallin A., Lléo A., Popp J., Martinez-Lage P. et al., 2021. Frontiers in aging neuroscience, 13 p. 712545. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D422EE00B545]
2020
 
Determinants of subjective cognitive decline in dementia‐free older adults: A population‐based study : Neuropsychology/Early detection of cognitive decline with neuropsychological tests
Zullo Leonardo, Clark Christopher, Popp Julius, 2020/12. Alzheimer's & Dementia, 16 (S6).
[DOI][serval:BIB_D5302911E1F6]
Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics.
Tijms B.M., Gobom J., Reus L., Jansen I., Hong S., Dobricic V., Kilpert F., Ten Kate M., Barkhof F., Tsolaki M. et al., 2020/12/01. Brain, 143 (12) pp. 3776-3792. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0AAA4F4517D4]
Conference report: dementia research and care and its impact in Switzerland.
Leyhe T., Jucker M., Nef T., Sollberger M., Riese F., Haba-Rubio J., Verloo H., Lüthi R., Becker S., Popp J., 2020/11/30. Swiss medical weekly, 150 pp. w20376. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_848D0C5FBC6D]
Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset.
Hong S., Prokopenko D., Dobricic V., Kilpert F., Bos I., Vos SJB, Tijms B.M., Andreasson U., Blennow K., Vandenberghe R. et al., 2020/11/22. Translational psychiatry, 10 (1) p. 403. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FC0401585DE0]
 
Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's disease.
Visser P.J., Reus L.M., Gobom J., Jansen I., Dicks E., Tsolaki M., Verhey FRJ, Popp J., Martinez-Lage P., Vandenberghe R. et al., 2020/11/03..
[DOI][Pmid][serval:BIB_7A7C72F36E10]
Preoperative Cognitive Impairment and Postoperative Delirium Predict Decline in Activities of Daily Living after Cardiac Surgery-A Prospective, Observational Cohort Study.
Guenther U., Hoffmann F., Dewald O., Malek R., Brimmers K., Theuerkauf N., Putensen C., Popp J., 2020/10/03. Geriatrics, 5 (4) pp. E69. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_412697178545]
 
Salivary cortisol and five-year change in cognitive performance in non-demented elderly subjects: a population-based study.
Ouanes S., Castelao E., von Gunten A., Kuehner C., Preisig M., Popp J., 2020/10. Neurobiology of aging, 94 pp. 34-37. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1611372EB072]
PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment.
Kleineidam L., Chouraki V., Próchnicki T., van der Lee S.J., Madrid-Márquez L., Wagner-Thelen H., Karaca I., Weinhold L., Wolfsgruber S., Boland A. et al., 2020/06. Acta neuropathologica, 139 (6) pp. 1025-1044. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A110BD6FC3A8]
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease.
Konijnenberg E., Tijms B.M., Gobom J., Dobricic V., Bos I., Vos S., Tsolaki M., Verhey F., Popp J., Martinez-Lage P. et al., 2020/05/27. Alzheimer's research & therapy, 12 (1) p. 65. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1ADD0E38A3F9]
Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer's disease.
Nasiri E., Sankowski R., Dietrich H., Oikonomidi A., Huerta P.T., Popp J., Al-Abed Y., Bacher M., 2020/04/17. Molecular medicine, 26 (1) p. 34. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0D1D163648E0]
Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology.
Shi L., Winchester L.M., Liu B.Y., Killick R., Ribe E.M., Westwood S., Baird A.L., Buckley N.J., Hong S., Dobricic V. et al., 2020. Journal of Alzheimer's disease, 77 (3) pp. 1353-1368. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F14D1CF79B2B]
 
Early-Stage Alzheimer's Disease Does Not Alter Pupil Responses to Colored Light Stimuli.
Kawasaki A., Ouanes S., Crippa S.V., Popp J., 2020. Journal of Alzheimer's disease, 75 (4) pp. 1273-1282. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_643E502B88F1]
Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.
Westwood S., Baird A.L., Anand S.N., Nevado-Holgado A.J., Kormilitzin A., Shi L., Hye A., Ashton N.J., Morgan A.R., Bos I. et al., 2020. Journal of Alzheimer's disease, 74 (1) pp. 213-225. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_24E3A61BAA92]
2019
Systemic and central nervous system metabolic alterations in Alzheimer's disease
van der Velpen Vera, Teav Tony, Gallart-Ayala Héctor, Mehl Florence, Konz Ioana, Clark Christopher, Oikonomidi Aikaterini, Peyratout Gwendoline, Henry Hugues, Delorenzi Mauro et al., 2019/12. Alzheimer's Research & Therapy, 11 (1). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_901648E242CF]
 
Systemic and central nervous system metabolic alterations in Alzheimer's disease.
van der Velpen V., Teav T., Gallart-Ayala H., Mehl F., Konz I., Clark C., Oikonomidi A., Peyratout G., Henry H., Delorenzi M. et al., 2019/11/28. Alzheimer's research & therapy, 11 (1) p. 93. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_359360363430]
Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.
Shi L., Westwood S., Baird A.L., Winchester L., Dobricic V., Kilpert F., Hong S., Franke A., Hye A., Ashton N.J. et al., 2019/11. Alzheimer's & dementia, 15 (11) pp. 1478-1488. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_70FCE73CB788]
Inflammatory biomarkers in Alzheimer's disease plasma.
Morgan A.R., Touchard S., Leckey C., O'Hagan C., Nevado-Holgado A.J., NIMA Consortium, Barkhof F., Bertram L., Blin O., Bos I. et al., 2019/06. Alzheimer's & dementia, 15 (6) pp. 776-787. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E5F2C092E354]
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.
Kim M., Snowden S., Suvitaival T., Ali A., Merkler D.J., Ahmad T., Westwood S., Baird A., Proitsi P., Nevado-Holgado A. et al., 2019/06. Alzheimer's & dementia, 15 (6) pp. 817-827. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7B445915312D]
 
Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
Bos I., Vos S., Verhey F., Scheltens P., Teunissen C., Engelborghs S., Sleegers K., Frisoni G., Blin O., Richardson J.C. et al., 2019/05. Alzheimer's & dementia, 15 (5) pp. 644-654. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DDAB35C4ACA0]
 
Proteomes of Paired Human Cerebrospinal Fluid and Plasma: Relation to Blood-Brain Barrier Permeability in Older Adults.
Dayon L., Cominetti O., Wojcik J., Galindo A.N., Oikonomidi A., Henry H., Migliavacca E., Kussmann M., Bowman G.L., Popp J., 2019/03/01. Journal of proteome research, 18 (3) pp. 1162-1174. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_47645F5F0BB7]
A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort.
Stamate D., Kim M., Proitsi P., Westwood S., Baird A., Nevado-Holgado A., Hye A., Bos I., Vos SJB, Vandenberghe R. et al., 2019. Alzheimer's & dementia, 5 pp. 933-938. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0E61EF2D9A41]
High Cortisol and the Risk of Dementia and Alzheimer's Disease: A Review of the Literature.
Ouanes S., Popp J., 2019. Frontiers in aging neuroscience, 11 p. 43. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D6B957F82431]
 
Preoperative Depression and Plasma Cortisol Levels as Predictors of Delirium after Cardiac Surgery
Eshmawey Mohamed, Arlt Sönke, Ledschbor-Frahnert Christine, Guenther Ulf, Popp Julius, 2019. Dementia and Geriatric Cognitive Disorders, 48 (3-4) pp. 207-214.
[DOI][WoS][Pmid][serval:BIB_D0FF2CE4C881]
2018
 
A global HILIC-MS approach to measure polar human cerebrospinal fluid metabolome: Exploring gender-associated variation in a cohort of elderly cognitively healthy subjects.
Gallart-Ayala H., Konz I., Mehl F., Teav T., Oikonomidi A., Peyratout G., van der Velpen V., Popp J., Ivanisevic J., 2018/12/11. Analytica chimica acta, 1037 pp. 327-337. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8774180E947C]
 
Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults.
Bowman G.L., Dayon L., Kirkland R., Wojcik J., Peyratout G., Severin I.C., Henry H., Oikonomidi A., Migliavacca E., Bacher M. et al., 2018/12. Alzheimer's & dementia, 14 (12) pp. 1640-1650. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0EFFC1931D8F]
LC-HRMS data as a result of untargeted metabolomic profiling of human cerebrospinal fluid.
Mehl F., Gallart-Ayala H., Konz I., Teav T., Oikonomidi A., Peyratout G., van der Velpen V., Popp J., Ivanisevic J., 2018/12. Data in brief, 21 pp. 1358-1362. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3087F712A56C]
The Effects of Hand Massage on Stress and Agitation Among People with Dementia in a Hospital Setting: A Pilot Study.
Schaub C., Von Gunten A., Morin D., Wild P., Gomez P., Popp J., 2018/12. Applied psychophysiology and biofeedback, 43 (4) pp. 319-332. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A529CB5ED27A]
MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.
Ten Kate M., Redolfi A., Peira E., Bos I., Vos S.J., Vandenberghe R., Gabel S., Schaeverbeke J., Scheltens P., Blin O. et al., 2018/09/27. Alzheimer's research & therapy, 10 (1) p. 100. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BD2694DB4008]
Do diurnal cortisol levels mediate the association between sleep disturbances and cognitive impairment?
Haba-Rubio J., Ouanes S., Franc Y., Marques-Vidal P., Waeber G., Vollenweider P., von Gunten A., Preisig M., Kuehner C., Castelao E. et al., 2018/09. Neurobiology of aging, 69 pp. 65-67. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9782E4869425]
Alzheimer disease pathology and the cerebrospinal fluid proteome.
Dayon L., Núñez Galindo A., Wojcik J., Cominetti O., Corthésy J., Oikonomidi A., Henry H., Kussmann M., Migliavacca E., Severin I. et al., 2018/07/18. Alzheimer's research & therapy, 10 (1) p. 66. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AAE843C84F72]
The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.
Bos I., Vos S., Vandenberghe R., Scheltens P., Engelborghs S., Frisoni G., Molinuevo J.L., Wallin A., Lleó A., Popp J. et al., 2018/07/06. Alzheimer's research & therapy, 10 (1) p. 64. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9FCF3DBEDCFC]
 
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.
Mattsson N., Groot C., Jansen W.J., Landau S.M., Villemagne V.L., Engelborghs S., Mintun M.M., Lleo A., Molinuevo J.L., Jagust W.J. et al., 2018/07. Alzheimer's & dementia, 14 (7) pp. 913-924. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2BF0DD8008FD]
 
Die Empfehlungen der Swiss Memory Clinics für die Diagnostik der Demenzerkrankungen [Recommendations of Swiss Memory Clinics for the Diagnosis of Dementia]
Bürge M., Bieri G., Brühlmeier M., Colombo F., Demonet J.F., Felbecker A., Georgescu D., Gietl A., Brioschi Guevara A., Jüngling F. et al., 2018/04. Praxis, 107 (8) pp. 435-451. Peer-reviewed.
[DOI][Pmid][serval:BIB_6BBF40EFD69D]
 
Recommandations de Swiss Memory Clinics pour le diagnostic des démences [Recommendations of Swiss Memory Clinics for the Diagnosis of Dementia]
Bürge M., Bieri G., Brühlmeier M., Colombo F., Demonet J.F., Felbecker A., Georgescu D., Gietl A., Brioschi Guevara A., Jüngling F. et al., 2018/04. Praxis, 107 (8) pp. 1-17. Peer-reviewed.
[DOI][Pmid][serval:BIB_7C939285E07D]
Etat confusionnel aigu de la personne âgée
von Gunten Armin, Baumgartner Markus, Georgescu Dan, Hafner Martina, Hasemann Wolfgang, Kressig Reto W., Popp Julius, Rohrbach Erich, Schmid Ruth, Verloo Henk et al., 2018/03/21. Forum Médical Suisse ‒ Swiss Medical Forum, 18 (12) pp. 277-284.
[URN][DOI][serval:BIB_62E51ED274AE]
 
Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.
Jansen W.J., Ossenkoppele R., Tijms B.M., Fagan A.M., Hansson O., Klunk W.E., van der Flier W.M., Villemagne V.L., Frisoni G.B., Fleisher A.S. et al., 2018/01/01. JAMA psychiatry, 75 (1) pp. 84-95. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FAF630BB763B]
2017
 
Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J., Gholamrezaee M., Henry H., von Gunten A., Popp J., 2017/12/15. Experimental gerontology, 100 pp. 45-53. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BBBB0FB80665]
 
Response to a letter to the editor: sleep disturbance as a stressor event in elderly's life.
Ouanes S., Haba-Rubio J., Popp J., 2017/12. Neurobiology of aging, 60 p. 204. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7FE46F1F8FBD]
Relations between personality changes and cerebrospinal fluid biomarkers of Alzheimer's disease pathology.
Tautvydaitė D., Antonietti J.P., Henry H., von Gunten A., Popp J., 2017/07. Journal of psychiatric research, 90 pp. 12-20. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0E83C16C1041]
One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond.
Dayon L., Guiraud S.P., Corthésy J., Da Silva L., Migliavacca E., Tautvydaitė D., Oikonomidi A., Moullet B., Henry H., Métairon S. et al., 2017/06/17. Alzheimer's research & therapy, 9 (1) p. 43. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C894918E7DAA]
 
ICP-MS/MS-Based Ionomics: A Validated Methodology to Investigate the Biological Variability of the Human Ionome.
Konz T., Migliavacca E., Dayon L., Bowman G., Oikonomidi A., Popp J., Rezzi S., 2017/05/05. Journal of proteome research, 16 (5) pp. 2080-2090. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CD4C6409C204]
 
Macrophage migration inhibitory factor is associated with biomarkers of Alzheimer's disease pathology and predicts cognitive decline in MCI and mild dementi
Popp J., Oikonomidi A., Tautvydaite D., Gholamrezaee M., Henry H., Bacher M., 2017/05/01., 13th International Conference on Alzheimer's and Parkinson's Diseases, AD/PD 2017 p. 394 dans Neurodegenerative Diseases.
[serval:BIB_F0AF02A84291]
Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J., Oikonomidi A., Tautvydaitė D., Dayon L., Bacher M., Migliavacca E., Henry H., Kirkland R., Severin I., Wojcik J. et al., 2017/04. Brain, behavior, and immunity, 62 pp. 203-211. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_13535C3E4C48]
Life events, salivary cortisol, and cognitive performance in nondemented subjects: a population-based study.
Ouanes S., Castelao E., Gebreab S., von Gunten A., Preisig M., Popp J., 2017/03. Neurobiology of aging, 51 pp. 1-8. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0083D52011B4]
Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer's disease pathology modulates cognitive performance.
Tautvydaitė D., Kukreja D., Antonietti J.P., Henry H., von Gunten A., Popp J., 2017/02/02. Alzheimer's research & therapy, 9 (1) p. 6. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_11AAF7C076DE]
 
Sleep characteristics and cognitive impairment in the general population: The HypnoLaus study.
Haba-Rubio J., Marti-Soler H., Tobback N., Andries D., Marques-Vidal P., Waeber G., Vollenweider P., von Gunten A., Preisig M., Castelao E. et al., 2017/01/31. Neurology, 88 (5) pp. 463-469. Peer-reviewed.
[DOI][Pmid][serval:BIB_32B36047428A]
 
Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
Oikonomidi A., Tautvydaitė D., Gholamrezaee M.M., Henry H., Bacher M., Popp J., 2017. Journal of Alzheimer's disease, 60 (1) pp. 273-281. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9B81B81A8AF4]
Neuroticism, depression, and anxiety traits exacerbate the state of cognitive impairment and hippocampal vulnerability to Alzheimer's disease
Zufferey Valérie, Donati Alessia, Popp Julius, Meuli Reto, Rossier Jérôme, Frackowiak Richard, Draganski Bogdan, von Gunten Armin, Kherif Ferath, 2017. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 7 pp. 107-114. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E041E3B7F170]
 
Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization.
Lewczuk P., Lelental N., Lachmann I., Holzer M., Flach K., Brandner S., Engelborghs S., Teunissen C.E., Zetterberg H., Molinuevo J.L. et al., 2017. Journal of Alzheimer's disease, 55 (1) pp. 159-170. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_17AF548CA0F8]
Personality, Cortisol, and Cognition in Non-demented Elderly Subjects: Results from a Population-Based Study.
Ouanes S., Castelao E., von Gunten A., Vidal P.M., Preisig M., Popp J., 2017. Frontiers in aging neuroscience, 9 p. 63. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_904D24B71915]
Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
Dayon L., Wojcik J., Núñez Galindo A., Corthésy J., Cominetti O., Oikonomidi A., Henry H., Migliavacca E., Bowman G.L., Popp J., 2017. Journal of Alzheimer's disease, 60 (4) pp. 1641-1652. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1A9D88852EEA]
2016
 
Empfehlungen zur Prävention, Diagnostik und Therapie des Delirs im Alter [Recommendations for prevention, diagnostic and therapy of delirium in the elderly]
Savaskan E., Baumgartner M., Georgescu D., Hafner M., Hasemann W., Kressig R.W., Popp J., Rohrbach E., Schmid R., Verloo H., 2016/08. Praxis, 105 (16) pp. 941-952. Peer-reviewed.
[DOI][Pmid][serval:BIB_B0EA8A9D5556]
 
L’agitation chez les personnes atteintes de démence : examen de la portée des connaissances et mise en perspective du phénomène selon la théorie du confort et le concept de l’attachement [Agitation in people with dementia : Scoping review and putting the phenomenon into perspective using the comfort theory and the concept of attachment]
Schaub C., Morin D., von Gunten A., 2016/06. Recherche en soins infirmiers, 125 pp. 68-83. Peer-reviewed.
[Pmid][serval:BIB_44A6B73BBC2F]
 
Les biomarqueurs du liquide céphalo-rachidien dans la maladie d'Alzheimer en pratique clinique courante [Cerebrospinal fluid biomarkers of Alzheimer's disease in current clinical practice].
Magnin E., Popp J., 2016/04. Revue Medicale Suisse, 12 (515) pp. 791-794. Peer-reviewed.
[Pmid][serval:BIB_EF61DD096D14]
 
Cortisol, life events and cognition in non-demented subjects: A population-based study
Ouanes S., Castelao E., Von Gunten A., Preisig M., Popp J., 2016/03. European Psychiatry, 33 (S1) pp. S77-S78.
[DOI][WoS][serval:BIB_C0E523F074A4]
 
Homocysteine metabolism is associated with cerebrospinal fluid levels of soluble amyloid precursor protein and amyloid beta.
Oikonomidi A., Lewczuk P., Kornhuber J., Smulders Y., Linnebank M., Semmler A., Popp J., 2016. Journal of Neurochemistry, 139 (2) pp. 324-332. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D232D8226BB8]
2015
Delirium in the elderly: Current problems with increasing geriatric age.
Kukreja D., Günther U., Popp J., 2015/12. The Indian journal of medical research, 142 (6) pp. 655-662. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_1E6538017A41]
 
Behavioral and psychological symptoms and cognitive decline in patients with amnestic MCI and mild AD: a two-year follow-up study.
Pocnet C., Antonietti J.P., Donati A., Popp J., Rossier J., von Gunten A., 2015. International Psychogeriatrics / Ipa, 27 (8) pp. 1379-1389. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_08BCB703154C]
 
Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J., Wolfsgruber S., Heuser I., Peters O., Hüll M., Schröder J., Möller H.J., Lewczuk P., Schneider A., Jahn H. et al., 2015. Neurobiology of Aging, 36 (2) pp. 601-607. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_13B364467755]
 
CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study.
Ewers M., Mattsson N., Minthon L., Molinuevo J.L., Antonell A., Popp J., Jessen F., Herukka S.K., Soininen H., Maetzler W. et al., 2015. Alzheimer's and Dementia, 11 (11) pp. 1306-1315. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6C1EDDC275C6]
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
Jansen W.J., Ossenkoppele R., Knol D.L., Tijms B.M., Scheltens P., Verhey F.R., Visser P.J., Amyloid Biomarker Study Group, Aalten P., Aalten P. et al., 2015. Jama, 313 (19) pp. 1924-1938. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8EDC5E63F9ED]
2014
 
Empfehlungen zur Diagnostik und Therapie der behavioralen und psychologischen Symptome der Demenz (BPSD) [Recommendations for diagnosis and therapy of behavioral and psychological symptoms in dementia (BPSD)].
Savaskan E., Bopp-Kistler I., Buerge M., Fischlin R., Georgescu D., Giardini U., Hatzinger M., Hemmeter U., Justiniano I., Kressig R.W. et al., 2014. Praxis, 103 (3) pp. 135-148. Peer-reviewed.
[DOI][Pmid][serval:BIB_88FC70E68B5A]
 
Subjective cognitive decline in patients with mild cognitive impairment and healthy older adults: Association with personality traits.
Studer J., Donati A., Popp J., von Gunten A., 2014. Geriatrics and Gerontology International, 14 (3) pp. 589-595. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6ED1A3D2882F]
 
SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.
Ramirez A., van der Flier W.M., Herold C., Ramonet D., Heilmann S., Lewczuk P., Popp J., Lacour A., Drichel D., Louwersheimer E. et al., 2014. Human Molecular Genetics, 23 (24) pp. 6644-6658. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_05087FA7722D]
2013
 
Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease.
Popp J., Meichsner S., Kölsch H., Lewczuk P., Maier W., Kornhuber J., Jessen F., Lütjohann D., 2013. Biochemical Pharmacology, 86 (1) pp. 37-42. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A54FC197196A]
 
Delirium and cognitive decline: more than a coincidence.
Popp J., 2013. Current Opinion in Neurology, 26 (6) pp. 634-639. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E00C946DF0AD]
 
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.
Dodel R., Rominger A., Bartenstein P., Barkhof F., Blennow K., Förster S., Winter Y., Bach J.P., Popp J., Alferink J. et al., 2013. Lancet Neurology, 12 (3) pp. 233-243. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F53D8B0D9CBA]
 
Predisposing and precipitating factors of delirium after cardiac surgery: a prospective observational cohort study.
Guenther U., Theuerkauf N., Frommann I., Brimmers K., Malik R., Stori S., Scheidemann M., Putensen C., Popp J., 2013. Annals of Surgery, 257 (6) pp. 1160-1167. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_540521397EA3]
 
The evolution of personality in patients with mild cognitive impairment.
Donati A., Studer J., Petrillo S., Pocnet C., Popp J., Rossier J., von Gunten A., 2013. Dementia and Geriatric Cognitive Disorders, 36 (5-6) pp. 329-339. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7104575BF305]
2012
 
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
Wagner M., Wolf S., Reischies F.M., Daerr M., Wolfsgruber S., Jessen F., Popp J., Maier W., Hüll M., Frölich L. et al., 2012. Neurology, 78 (6) pp. 379-386. Peer-reviewed.
[DOI][Pmid][serval:BIB_E4BD5DAEAE48]
 
Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease.
Lewczuk P., Popp J., Lelental N., Kölsch H., Maier W., Kornhuber J., Jessen F., 2012. Journal of Alzheimer's Disease, 28 (1) pp. 119-125. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DE82EAE7E6C6]
 
Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease.
Popp J., Lewczuk P., Kölsch H., Meichsner S., Maier W., Kornhuber J., Jessen F., Lütjohann D., 2012. Journal of Neurochemistry, 123 (2) pp. 310-316. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C1631EB9C20E]
 
Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients.
Rogacev K.S., Pinsdorf T., Weingärtner O., Gerhart M.K., Welzel E., van Bentum K., Popp J., Menzner A., Fliser D., Lütjohann D. et al., 2012. Clinical Journal of the American Society of Nephrology, 7 (6) pp. 943-948. Peer-reviewed.
[DOI][Pmid][serval:BIB_58F16C6BB5C0]
 
Determinants of the essential one-carbon metabolism metabolites, homocysteine, S-adenosylmethionine, S-adenosylhomocysteine and folate, in cerebrospinal fluid.
Smith D.E., Smulders Y.M., Blom H.J., Popp J., Jessen F., Semmler A., Farkas M., Linnebank M., 2012. Clinical Chemistry and Laboratory Medicine, 50 (9) pp. 1641-1647. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E62D0F50571A]
 
Differentially expressed gene profile in the 6-hydroxy-dopamine-induced cell culture model of Parkinson's disease.
Noelker C., Schwake M., Balzer-Geldsetzer M., Bacher M., Popp J., Schlegel J., Eggert K., Oertel W.H., Klockgether T., Dodel R.C., 2012. Neuroscience Letters, 507 (1) pp. 10-15. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_119B3D9C5371]
 
Dimethylarginines, homocysteine metabolism, and cerebrospinal fluid markers for Alzheimer's disease.
Arlt S., Schwedhelm E., Kölsch H., Jahn H., Linnebank M., Smulders Y., Jessen F., Böger R.H., Popp J., 2012. Journal of Alzheimer's Disease : Jad, 31 (4) pp. 751-758. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F82C79E379FF]
 
Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment.
Scheef L., Spottke A., Daerr M., Joe A., Striepens N., Kölsch H., Popp J., Daamen M., Gorris D., Heneka M.T. et al., 2012. Neurology, 79 (13) pp. 1332-1339. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FAD2136DA3E3]
 
Implications of Objective vs Subjective Delirium Assessment in Surgical Intensive Care Patients.
Guenther U., Weykam J., Andorfer U., Theuerkauf N., Popp J., Ely E.W., Putensen C., 2012. American Journal of Critical Care : An Official Publication, American Association of Critical-care Nurses, 21 (1) pp. e12-e20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_32F024D33547]
 
Prevention and treatment options for postoperative delirium in the elderly.
Popp J., Arlt S., 2012. Current Opinion In Psychiatry, 25 (6) pp. 515-521. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0C512B0615F6]
2011
 
Association of N-acetylaspartate and cerebrospinal fluid Aβ42 in dementia.
Jessen F., Lewczuk P., Gür O., Block W., Ende G., Frölich L., Hammen T., Arlt S., Kornhuber J., Kucinski T. et al., 2011. Journal of Alzheimer's Disease, 27 (2) pp. 393-399. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_049C4F0B7D4F]
 
Interaction effects of subjective memory impairment and ApoE4 genotype on episodic memory and hippocampal volume.
Striepens N., Scheef L., Wind A., Meiberth D., Popp J., Spottke A., Kölsch H., Wagner M., Jessen F., 2011. Psychological Medicine, 41 (9) pp. 1997-2006. Peer-reviewed.
[DOI][Pmid][serval:BIB_6CD3E4656E26]
 
Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease.
Popp J., Arlt S., 2011. Current Opinion In Psychiatry, 24 (6) pp. 556-561. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C1AB716A4D8B]
 
The plant sterol brassicasterol as additional CSF biomarker in Alzheimer's disease.
Vanmierlo T., Popp J., Kölsch H., Friedrichs S., Jessen F., Stoffel-Wagner B., Bertsch T., Hartmann T., Maier W., von Bergmann K. et al., 2011. Acta Psychiatrica Scandinavica, 124 (3) pp. 184-192. Peer-reviewed.
[DOI][Pmid][serval:BIB_0BBFFEE1D3CB]
2010
 
Alterations of cholesterol precursor levels in Alzheimer's disease.
Kölsch H., Heun R., Jessen F., Popp J., Hentschel F., Maier W., Lütjohann D., 2010. Biochimica et Biophysica Acta, 1801 (8) pp. 945-950. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1308830CA8C7]
 
Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.
Popp J., Lewczuk P., Frommann I., Kölsch H., Kornhuber J., Maier W., Jessen F., 2010. Journal of Alzheimer's Disease : Jad, 22 (2) pp. 459-468. Peer-reviewed.
[DOI][Pmid][serval:BIB_132DD7B90805]
 
S-adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease.
Linnebank M., Popp J., Smulders Y., Smith D., Semmler A., Farkas M., Kulic L., Cvetanovska G., Blom H., Stoffel-Wagner B. et al., 2010. Neuro-degenerative Diseases, 7 (6) pp. 373-378. Peer-reviewed.
[DOI][Pmid][serval:BIB_D91B8CD041C2]
 
Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
Lewczuk P., Kamrowski-Kruck H., Peters O., Heuser I., Jessen F., Popp J., Bürger K., Hampel H., Frölich L., Wolf S. et al., 2010. Molecular Psychiatry, 15 (2) pp. 138-145. Peer-reviewed.
[DOI][Pmid][serval:BIB_87F8116B7F24]
 
The role of macrophage migration inhibitory factor in Alzheimer's disease.
Bacher M., Deuster O., Aljabari B., Egensperger R., Neff F., Jessen F., Popp J., Noelker C., Reese J.P., Al-Abed Y. et al., 2010. Molecular Medicine (cambridge, Mass.), 16 (3-4) pp. 116-121. Peer-reviewed.
[DOI][Pmid][serval:BIB_51D50F0FE5BE]
 
Validity and reliability of the CAM-ICU Flowsheet to diagnose delirium in surgical ICU patients.
Guenther U., Popp J., Koecher L., Muders T., Wrigge H., Ely E.W., Putensen C., 2010. Journal of Critical Care, 25 (1) pp. 144-151. Peer-reviewed.
[DOI][Pmid][serval:BIB_88E0E4809C86]
 
Volume loss of the medial temporal lobe structures in subjective memory impairment.
Striepens N., Scheef L., Wind A., Popp J., Spottke A., Cooper-Mahkorn D., Suliman H., Wagner M., Schild H.H., Jessen F., 2010. Dementia and Geriatric Cognitive Disorders, 29 (1) pp. 75-81. Peer-reviewed.
[DOI][Pmid][serval:BIB_3B4AC3A1CF80]
2009
 
Association of CETP polymorphisms with the risk of vascular dementia and white matter lesions.
Qureischie H., Heun R., Popp J., Jessen F., Maier W., Schmitz S., Hentschel F., Kelemen P., Kölsch H., 2009. Journal of Neural Transmission (vienna, Austria : 1996), 116 (4) pp. 467-472. Peer-reviewed.
[DOI][Pmid][serval:BIB_EB47A04A38FC]
 
CSF cortisol in Alzheimer's disease and mild cognitive impairment.
Popp J., Schaper K., Kölsch H., Cvetanovska G., Rommel F., Klingmüller D., Dodel R., Wüllner U., Jessen F., 2009. Neurobiology of Aging, 30 (3) pp. 498-500. Peer-reviewed.
[DOI][Pmid][serval:BIB_B191279EFFFE]
 
CYP46A1 variants influence Alzheimer's disease risk and brain cholesterol metabolism.
Kölsch H., Lütjohann D., Jessen F., Popp J., Hentschel F., Kelemen P., Schmitz S., Maier W., Heun R., 2009. European Psychiatry : the Journal of the Association of European Psychiatrists, 24 (3) pp. 183-190. Peer-reviewed.
[DOI][Pmid][serval:BIB_2FD1C826DBB5]
 
Deutsche Kurzversion: Confusion Assessment Method for Intensive Care Unit zur routine­mäßigen Kontrolle des Delirs auf Intensivstation = German short version of the Confusion Assessment Method for the Intensive Care Unit for routine delirium monitoring
Günther U., Muders T., Wrigge H., Popp J., Andorfer U., Putensen C., 2009. Anaesthesiologie und Intensivmedizin, 50 (10) pp. 592-600. Peer-reviewed.
[serval:BIB_5CE74DC75F47]
 
Gene variations in GSTM3 are a risk factor for Alzheimer's disease.
Hong G.S., Heun R., Jessen F., Popp J., Hentschel F., Kelemen P., Schulz A., Maier W., Kölsch H., 2009. Neurobiology of Aging, 30 (5) pp. 691-696. Peer-reviewed.
[DOI][Pmid][serval:BIB_CCC0A041830E]
 
Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease.
Popp J., Lewczuk P., Linnebank M., Cvetanovska G., Smulders Y., Kölsch H., Frommann I., Kornhuber J., Maier W., Jessen F., 2009. Journal of Alzheimer's Disease, 18 (4) pp. 819-828. Peer-reviewed.
[DOI][Pmid][serval:BIB_3319306D538E]
 
Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease.
Popp J., Bacher M., Kölsch H., Noelker C., Deuster O., Dodel R., Jessen F., 2009. Journal of Psychiatric Research, 43 (8) pp. 749-753. Peer-reviewed.
[DOI][Pmid][serval:BIB_9C07CE4634D3]
 
Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form.
Klafki H.W., Lewczuk P., Kamrowski-Kruck H., Maler J.M., Müller K., Peters O., Heuser I., Jessen F., Popp J., Frölich L. et al., 2009. Journal of Alzheimer's Disease : Jad, 18 (3) pp. 613-622. Peer-reviewed.
[DOI][Pmid][serval:BIB_03F04FC77E20]
 
Plasma homocysteine and cerebrospinal fluid neurodegeneration biomarkers in mild cognitive impairment and dementia.
Alexopoulos P., Günther F., Popp J., Jessen F., Peters O., Wolf S., Kneib T., Kurz A., Richter-Schmidinger T., Lewczuk P. et al., 2009. Journal of the American Geriatrics Society, 57 (4) pp. 737-739. Peer-reviewed.
[Pmid][serval:BIB_EE3CABFC224F]
 
RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism.
Kölsch H., Lütjohann D., Jessen F., Popp J., Hentschel F., Kelemen P., Friedrichs S., Maier T.A., Heun R., 2009. Journal of Cellular and Molecular Medicine, 13 (3) pp. 589-598. Peer-reviewed.
[DOI][Pmid][serval:BIB_28A8D2EEBF99]
2008
 
CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk.
Qureischie H., Heun R., Lütjohann D., Popp J., Jessen F., Ledschbor-Frahnert C., Thiele H., Maier W., Hentschel F., Kelemen P. et al., 2008. Brain Research, 1232 pp. 1-6. Peer-reviewed.
[DOI][Pmid][serval:BIB_E3D0251C82E6]
 
KIBRA gene variants are associated with episodic memory in healthy elderly.
Schaper K., Kolsch H., Popp J., Wagner M., Jessen F., 2008. Neurobiology of Aging, 29 (7) pp. 1123-1125. Peer-reviewed.
[DOI][Pmid][serval:BIB_A83D9E4F2373]
2007
 
Ambulante Durchführung einer diagnostischen Lumbalpunktion in der Gedächtnissprechstunde. Häufigkeit und Risikofaktoren eines postpunktionellen Syndroms [Diagnostic lumbar puncture performed in the outpatient setting of a memory clinic. Frequency and risk factors of post-lumbar puncture headache].
Popp J., Riad M., Freymann K., Jessen F., 2007. Der Nervenarzt, 78 (5) pp. 547-551. Peer-reviewed.
[DOI][Pmid][serval:BIB_1995D0AB99C5]
 
Histologically confirmed amyloid deposition and low CSF Abeta42 in a cognitively normal subject.
Popp J., Thal D.R., Lewczuk P., Wiltfang J., Jessen F., 2007. Journal of Neurology, 254 (7) pp. 970-971. Peer-reviewed.
[DOI][Pmid][serval:BIB_00CEBA9F9D2C]
2004
 
Mechanical ventilation in ischemic stroke.
Milhaud D., Popp J., Thouvenot E., Heroum C., Bonafé A., 2004. Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association, 13 (4) pp. 183-188. Peer-reviewed.
[DOI][Pmid][serval:BIB_F26CB3DD8F1B]
1998
 
Angiogenesis and brain oedema in intracranial meningiomas: influence of vascular endothelial growth factor.
Bitzer M., Opitz H., Popp J., Morgalla M., Gruber A., Heiss E., Voigt K., 1998. Acta Neurochirurgica, 140 (4) pp. 333-340. Peer-reviewed.
[Pmid][serval:BIB_122A6BC7A59D]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University